Literature DB >> 20838835

The continuous measurement of anti-CCP-antibodies does not help to evaluate the disease activity in anti-CCP-antibody-positive patients with rheumatoid arthritis.

Thoren Landmann1, Gabriele Kehl, Raoul Bergner.   

Abstract

Anti-cyclic citrullinated peptide antibody (CCP-AB) are used for diagnosis of rheumatoid arthritis (RA). It is still unknown if the extent of CCP-AB levels is useful to assess the disease activity or the individual follow-up as an individual activity parameter. We investigated 40 patients with a known RA who were positive for CCP-AB. Correlation between disease activity (DAS 28) and the amount of levels of CCP-AB in all patients over time as well as the individual follow-up were analysed. A weak correlation between CCP-AB and DAS 28 [r = 0.19; p = 0.001] was found. The individual correlation between CCP-AB titre and DAS 28 ranged between r = -1 and r = 1, so a strong positive and also a strong negative correlation was seen in single patients. In patients with erosive RA the correlation was significantly more positive than in patients with non-erosive RA. Because the correlation between CCP-AB levels and parameters of disease activity measured by DAS 28 is very low, we conclude for monitoring the disease activity to use simply and established parameters like morning stiffness, HAQ or ESR. The individual follow-up of the levels of CCP-AB is by the moment not useful for monitoring the disease activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20838835     DOI: 10.1007/s10067-010-1557-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  17 in total

1.  Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset.

Authors:  E Berglin; T Johansson; U Sundin; E Jidell; G Wadell; G Hallmans; S Rantapää-Dahlqvist
Journal:  Ann Rheum Dis       Date:  2005-09-21       Impact factor: 19.103

2.  Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA.

Authors:  Sumeet Agrawal; Ramnath Misra; Amita Aggarwal
Journal:  Clin Rheumatol       Date:  2006-03-30       Impact factor: 2.980

3.  The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.

Authors:  H A Chen; K C Lin; C H Chen; H T Liao; H P Wang; H N Chang; C Y Tsai; C T Chou
Journal:  Ann Rheum Dis       Date:  2005-06-23       Impact factor: 19.103

Review 4.  Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review.

Authors:  J Avouac; L Gossec; M Dougados
Journal:  Ann Rheum Dis       Date:  2006-04-10       Impact factor: 19.103

5.  The predictive value of rheumatoid factor isotypes, anti-cyclic citrullinated peptide antibodies, and antineutrophil cytoplasmic antibodies for mortality in patients with rheumatoid arthritis.

Authors:  Susanna Sihvonen; Markku Korpela; Anu Mustila; Jukka Mustonen
Journal:  J Rheumatol       Date:  2005-11       Impact factor: 4.666

6.  Anti-CCP2 is an adjunct to, not a surrogate for, rheumatoid factor in the diagnosis of rheumatoid arthritis: diagnostic utility of anti-CCP2 antibodies in Egyptian patients with rheumatoid arthritis.

Authors:  A M Abdel-Nasser; M H Mahmoud; T M El Mansoury; A M Osman
Journal:  Scand J Rheumatol       Date:  2008 Sep-Oct       Impact factor: 3.641

7.  Association of anti-CCP positivity with serum ferritin and DAS-28.

Authors:  Burcu Önder; Aydan Kurtaran; Songül Kimyon; Barin Selçuk; Müfit Akyüz
Journal:  Rheumatol Int       Date:  2009-12       Impact factor: 2.631

8.  Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement.

Authors:  C Alessandri; M Bombardieri; N Papa; M Cinquini; L Magrini; A Tincani; G Valesini
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

Review 9.  Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis.

Authors:  Kunihiro Nishimura; Daisuke Sugiyama; Yoshinori Kogata; Goh Tsuji; Takashi Nakazawa; Seiji Kawano; Katsuyasu Saigo; Akio Morinobu; Masahiro Koshiba; Karen M Kuntz; Isao Kamae; Shunichi Kumagai
Journal:  Ann Intern Med       Date:  2007-06-05       Impact factor: 25.391

10.  Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis.

Authors:  C Potter; K L Hyrich; A Tracey; M Lunt; D Plant; D P M Symmons; W Thomson; J Worthington; P Emery; A W Morgan; A G Wilson; J Isaacs; A Barton
Journal:  Ann Rheum Dis       Date:  2008-03-28       Impact factor: 19.103

View more
  6 in total

1.  Serum anti-cyclic citrullinated peptide antibodies may predict disease activity in rheumatoid arthritis.

Authors:  Kamal Esalatmanesh; Raika Jamali; Arsia Jamali; Bardia Jamali; Mohammadreza Nikbakht
Journal:  Rheumatol Int       Date:  2011-12-21       Impact factor: 2.631

Review 2.  Coeliac disease and rheumatoid arthritis: similar mechanisms, different antigens.

Authors:  Frits Koning; Ranjeny Thomas; Jamie Rossjohn; Rene E Toes
Journal:  Nat Rev Rheumatol       Date:  2015-05-19       Impact factor: 20.543

3.  Anti-citrullinated glucose-6-phosphate isomerase peptide antibodies in patients with rheumatoid arthritis are associated with HLA-DRB1 shared epitope alleles and disease activity.

Authors:  N Umeda; I Matsumoto; I Ito; A Kawasaki; Y Tanaka; A Inoue; H Tsuboi; T Suzuki; T Hayashi; S Ito; N Tsuchiya; T Sumida
Journal:  Clin Exp Immunol       Date:  2013-04       Impact factor: 4.330

Review 4.  The B cell response to citrullinated antigens in the development of rheumatoid arthritis.

Authors:  Hans Ulrich Scherer; Tom W J Huizinga; Gerhard Krönke; Georg Schett; Rene E M Toes
Journal:  Nat Rev Rheumatol       Date:  2018-02-08       Impact factor: 20.543

5.  Rheumatoid factor and anti-citrullinated protein antibody positivity, but not level, are associated with increased mortality in patients with rheumatoid arthritis: results from two large independent cohorts.

Authors:  Jennifer H Humphreys; Jessica A B van Nies; Jackie Chipping; Tarnya Marshall; Annette H M van der Helm-van Mil; Deborah P M Symmons; Suzanne M M Verstappen
Journal:  Arthritis Res Ther       Date:  2014-12-04       Impact factor: 5.156

6.  Antibodies against citrullinated proteins in relation to periodontitis with or without rheumatoid arthritis: a cross-sectional study.

Authors:  Pit Hui Lew; Mohammad Tariqur Rahman; Syarida Hasnur Safii; Nor Adinar Baharuddin; Peter Mark Bartold; Sargunan Sockalingam; Noor Lide Abu Kassim; Rathna Devi Vaithilingam
Journal:  BMC Oral Health       Date:  2021-07-20       Impact factor: 2.757

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.